Danaher Corporation $DHR Stock Holdings Lifted by Candriam S.C.A.

Candriam S.C.A. grew its position in shares of Danaher Corporation (NYSE:DHR) by 12.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 451,933 shares of the conglomerate’s stock after buying an additional 49,409 shares during the quarter. Candriam S.C.A. owned approximately 0.06% of Danaher worth $89,279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Danaher in the first quarter worth approximately $833,941,000. Generation Investment Management LLP lifted its stake in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. Invesco Ltd. boosted its holdings in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. increased its position in Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC boosted its stake in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $219.60 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The company’s fifty day moving average is $204.76 and its two-hundred day moving average is $200.77. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The firm has a market capitalization of $155.11 billion, a price-to-earnings ratio of 45.28, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period last year, the business earned $1.71 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is 26.39%.

Analyst Ratings Changes

DHR has been the subject of several analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research note on Tuesday, September 2nd. Finally, Robert W. Baird set a $247.00 target price on shares of Danaher in a research report on Wednesday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 11.20% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.